Acquired Resistance to Immune Checkpoint InhibitorsAdam J. Schoenfeld, Matthew D. Hellmann|Cancer Cell|2020Cited by 927
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinibAdam J. Schoenfeld, Matthew D. Hellmann, Kathryn C. Arbour et al.|Annals of Oncology|2019Cited by 413
Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in <i>EGFR</i> -Mutant Lung CancerAdam J. Schoenfeld, Helena A. Yu, Joseph M. Chan et al.|Clinical Cancer Research|2020Cited by 381
Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non–Small-Cell Lung Cancer in CheckMate 227Julie R. Brahmer, Suresh S. Ramalingam, Jong-Seok Lee et al.|Journal of Clinical Oncology|2022Cited by 375
SMARCA4-Deficient Thoracic Sarcomatoid Tumors Represent Primarily Smoking-Related Undifferentiated Carcinomas Rather Than Primary Thoracic SarcomasNatasha Rekhtman, William D. Travis, Achim A. Jungbluth et al.|Journal of Thoracic Oncology|2019Cited by 307